[{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Confirms First-to-File Patent Challenge For Generic Version Of Eucrisa\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Padagis","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sol-Gel Technologies Announces Sale of Generic Dermatology Portfolio to Partner Padagis for $21 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces The FDA Approval And Launch Of an Ab Rated Generic Version Of Tobradex\u00ae Ophthalmic Suspension","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces the First-to-Market Launch of an AB Rated Generic Version Of Zomig\u00ae Nasal Spray","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Padagis","sponsor":"Ayana Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces the FDA Approval and Launch of an AB Rated Generic Version of Doxil\u00ae (Doxorubicin Liposome Injection)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Padagis","sponsor":"Moberg Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moberg Pharma and Padagis Sign Agreement For MOB-015 in Israel","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces 3 Major Product Launches","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces the FDA Approval and Launch of an AB Rated Generic Version of Tobradex\u00ae Ophthalmic Suspension","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces FDA Approval and Launch of A-Rated Generic Version of Uceris\u00ae (budesonide 2 Mg Rectal Foam)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces the First Generic Over-the-Counter Approval of a Naloxone Nasal Spray Product","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces the First Launch of an Over-the-counter Naloxone Nasal Spray in The United States","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces the Launch of Brinzolamide Ophthalmic Suspension with CGT Exclusivity","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Padagis","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve\u00ae Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Padagis
Zoryve-Generic (roflumilast), PDE4 Inhibitor, small molecule. It is a topical cream indicated for the treatment of plaque psoriasis in patients six years of age and older.
Brinzolamide, generic equivalent to the Reference Listed Drug Azopt Ophthalmic Suspension, is indicated to decrease elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma.
Naloxone HCl Nasal Spray is the opioid antagonists indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.
Naloxone hydrochloride nasal spray, as an OTC emergency treatment for known or suspected opioid overdose. Naloxone hydrochloride is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites, which is investigated for the treatment of Multiple Sclerosis.
Budesonide is a prescription corticosteroid medicine used to help get active, mild to moderate ulcerative colitis that extends from the rectum to the sigmoid colon under control (induce remission).
Under the agreement Padagis is granted exclusive rights to market and sell MOB-015 (terbinafine hydrochloride) in Israel and the Palestinian territories. Moberg Pharma assumes production and supply responsibility.
Naloxone Nasal Spray, 4mg (generic to Narcan®),is a prescription medicine used for the treatment of a known or suspected opioid overdose emergency with signs of breathing problems and severe sleepiness or not being able to respond.
Tobradex® Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
Tobramycin (generic to Tobradex) Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
Zomig® Nasal Spray is distributed in a unique unit dose presentation and is indicated for the treatment of migraine headaches with or without aura in adults and pediatric patients (12 to 17 years of age).
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
